Introduction
Development and progression of autoimmune disorders (AID), such as type 1 diabetes (T1D), celiac disease (CD) and rheumatoid arthritis (RA), is a multifactorial process that depends on the combination of genetic and environmental factors. In the past decades, extensive efforts have been made to unraveling the genetic background of autoimmune disease. This has resulted in identification of several genetic risk factors that are associated with AID. 1, 2 It is clear that the pathophysiology of autoimmune diseases is for a large part T-cell mediated, and it is therefore not surprising that genetics risk factors are often shared between different autoimmune diseases. 3 The most notable example is the HLA system, which is associated with many, if not all, autoimmune diseases. Recently, strong association has been initially reported for a coding SNP in the PTPN22 gene (1858C4 T, rs2476601) with T1D, [4] [5] [6] which subsequently was shown to be associated to RA, 7 systemic lupus erythematosus (SLE), 8 Graves disease (GD) 5,9 and Addison's disease. 9 PTPN22 encodes a lymphoid protein tyrosine kinase (LYP) that is involved in negative control of T-cell activation and proliferation. This negative control is exhibited through the interaction of LYP with the C-terminal Src tyrosine kinase (CSK) that inhibits the TCR signaling. 10 The R620W substitution disrupt the LYP-CSK interactions 4, 11 and may therefore lead to uninhibited TCR signaling, and thus increased T-cell activation.
The finding that PTPN22 is associated to several autoimmune diseases may reflect its general role in the etiology of autoimmunity. Therefore, we sought to confirm the association of PTPN22 1858*T allele in a Dutch T1D and RA cohort, and in addition test a CD cohort, for which no previous study of PTPN22 has been reported.
Results and discussion

Type 1 diabetes
The PTPN22*1858C4T variant was tested in a juvenile onset T1D cohort consisting of 218 simplex families and in case-control cohort of 334 cases and 528 controls. The age at onset of the T1D patients was on average 8.7 years (range 1-17 years). Strong association of PTPN22 with T1D was observed both in case-control design and by the TDT analysis of the simplex families. The frequency of the 1858*T allele was increased in T1D cases (18.0%) compared to controls (8.7%) (P ¼ 2E-07, OR ¼ 2.3, 95%CI ¼ 1.7-3.1) ( Table 1) . Similarly, the 1858*T allele was preferentially transmitted to T1D patients Table 2 ). The homozygous TT genotype conferred higher risk than the heterozygous genotype (OR of PTPN22*TT is 5.05 (CI ¼ 1.7-15), OR of PTPN22*TC is 2.2 (CI ¼ 1.6-3.1)). No effect was found for gender or HLA stratification.
Rheumatoid arthritis
Association with PTPN22 was also confirmed in a Dutch cohort consisting of 151 RA patients. The frequency of the 1858*T allele was increased in RA patients compared to controls (14.6 vs 8.7%, P ¼ 0.003, OR ¼ 1.8 CI ¼ 1.2-2.6) ( Table 1 ). It has previously been reported that the association with 1858C4T was observed only in rheumatoid factor (RF) positive, but not in RF negative RA patients. 7 Therefore, association of PTPN22*T allele was recalculated in patients stratified for the presence or RF. Of the 67 patients of which RF data were available, 52 were RF positive and 15 RF negative. Indeed, the frequency of 1858*T allele was increased compared to controls only in the RF þ group, but statistical significance was not reached most likely due to the small sample size (13.5 and 6.7% respectively, P ¼ NS). No effect was found for the patients' gender, while HLA and age stratifications could not be performed due to incomplete HLA typing and unknown age at clinical onset of the disease.
Celiac disease
We further investigated PTPN22 in 123 simplex CD families, and in a cohort of 309 CD patients. All CD patients were diagnosed according to the revised ESPGAN criteria. 12 In addition, for all patients the intestinal biopsy on which the initial diagnosis was performed were re-evaluated by an experienced pathologist and only patients with a Marsh III lesion were included in the study. 13 In the total CD group, the 1858C/T allele and genotype frequencies were not statistically different from controls, although there was a slight increase in homozygous TT genotype in patients (P ¼ 0.048, Fisher exact test) (Table 1) . Furthermore, no preferential transmission was observed in the CD families (data not shown). No effect was found on gender or HLA. However, the effect of the PTPN22 was more prominent in cases with early development of clinical symptoms, or the 'pediatric' group (diagnosed o10 years, n ¼ 88), compared to the 'adult' onset group (diagnosed 420 years, n ¼ 199) ( Table 3 ). The genotype distribution in the o10 years group was different from controls (P ¼ 0.01), mainly caused by the excess of homozygous TT-homozygous cases (OR for TT genotype 6.2, 95% CI ¼ 1.6-23.3). However, these results should be confirmed in other cohorts considering the low number of TT-homozygous subjects. OR-odds ratio, CI-95% confidence interval. The PTPN22*1858C4T SNP was genotyped using Taqman Assay-by-Design (Applied Biosystems). The following primers and probes were used: forward primer: CCAGCTTCCTCAACCACAATAAATG, reverse primer: CAACTGCTCCAAGGATAGATGATGA, VIC reporter: TTCAGGTGTCCGTACAGG, FAM reporter: CAGGTGTCCATACAGG. Assays were performed according to the manufacturer's specifications. The genotypes were analyzed using a TaqMan 7900HT (Applied Biosystems). The DNA samples were processed in 384-well plates and each plate contained eight negative controls and 16 genotyping controls (four duplicates of four different CEPH samples). Differences in allele and genotype distribution in cases and controls were tested for significance using the w 2 test. Genotypes of controls were in Hardy-Weinberg equilibrium (HWE). For HWE we compared the expected and observed genotypes in 2 Â 3 w 2 tables. Odds ratios and confidence intervals were calculated using Woolf's method with Haldane's correction. T-transmitted, NT-non-transmitted, OR-odds ratio, CI-95% confidence interval. Association in the families was tested by TDT using the TDT phase program in the UNPHASED package of the GLUE program (http://menu.hgmp.mrc.ac.uk/menu-bin/GLUE/ glue.pl). OR-odds ratio, CI-95% confidence interval. The CD group was split into two groups: one diagnosed before 10 years of age (n ¼ 88) and one diagnosed after 20 years of age (n ¼ 199). Patients diagnosed between the age of 10 and 20 (n ¼ 13) and with an unknown age of diagnosis (n ¼ 9) were excluded from the calculations.
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Conclusions
Here we confirmed the association of the PTPN22* 1858C4T polymorphism in a Dutch cohort of juvenile T1D patients and a RA cohort. This observation further strengthens the evidence that PTPN22 is an important genetic risk factor for autoimmune diseases. In contrast, no convincing association was found for another autoimmune disease, namely celiac disease, although a suggestive effect was found when patients were stratified for early age at onset of CD. Lack of association with PTPN22 has also been reported for another presumed AID, multiple sclerosis. 14 Possible explanation for this lack of association may be a different role of T-cell dependent autoimmunity in the latter two diseases, but false-negative results cannot be ruled out.
The observed association of the 1858C4T SNP with the T1D was more prominent than reported previously. [4] [5] [6] It is tempting to speculate that the higher association in our population may be correlated with the early age of onset of the disease in our group (average age of onset 8.7 years), and that the impaired negative control of Tcell activation might lead to the earlier manifestation of the disease. The effect on age at onset found in the celiac patients may further strengthen this observation. However, the effect of PTPN22 on age of manifestation of disease needs further study, preferably in pediatric cohorts.
Materials and methods
Information about materials and methods is available in the supplementary information online (http://humgen. med.uu.nl/publications).
